Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9491373 | 0.86 | ALDH1A1 (0.45) | DRD3ALDH1A1KMT2AMAPT | |
| SCHEMBL29783582 | 0.86 | ALDH1A1 (0.45) | DRD3ALDH1A1KMT2AMAPT | |
| SCHEMBL9342981 | 0.82 | ALDH1A1 (0.52) | DRD3ALDH1A1KMT2A | |
| SCHEMBL31758137 | 0.82 | ALDH1A1 (0.52) | DRD3ALDH1A1KMT2A | |
| SCHEMBL4581089 | 0.82 | DRD3 (0.42) | DRD3ALDH1A1KMT2A | |
| SCHEMBL7522120 | 0.81 | MAOB (0.42) | DRD3ALDH1A1MAOBKMT2A | |
| SCHEMBL16307244 | 0.80 | CES1 (0.48) | DRD3ALDH1A1KMT2A | |
| SCHEMBL18256567 | 0.80 | CES1 (0.48) | DRD3ALDH1A1KMT2A | |
| SCHEMBL18248457 | 0.80 | CES1 (0.48) | DRD3ALDH1A1KMT2A | |
| SCHEMBL26722458 | 0.80 | CES1 (0.48) | DRD3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080160594-A1 | Methods of Light Activated Release of Ligands from Endosomes | INVITROGEN CORPORATION (US) | 2008-07-03 | — | — | US | disclosed |
| EP-0731807-B1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030031655-A1 | Methods of light activated release of ligands from endosomes | SEQUITUR, INC. (US) | 2003-02-13 | — | — | US | disclosed |
| WO-2002062989-A2 | METHODS OF LIGHT ACTIVATED RELEASE 0F LIGANDS FROM ENDOSOMES | SEQUITUR, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0635023-B1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2002-02-06 | — | — | EP | disclosed |
| US-6232463-B1 | CROSSLINKING OLIGONUCLEOTIDES CONTAINING PURINE ANALOGS HAVING REACTIVE SITES ON THE NUCLEOBASE AND ON A SUGAR MOIETY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6166199-A | N-2 substituted purines | ISIS PHARMACEUTICALS, INC (US) | 2000-12-26 | — | — | US | disclosed |
| US-6127124-A | MONITORING THE STABILTY OF AN OLIGOMER TO ENZYMATIC DIGESTION; DIGESTING OLIGONUCLEOTIDE, SUBJECTING DIGESTION MIXTURE TO ELECTROPHORESIS, DETECTING DIGESTION PRODUCTS BY FLUORESENCE | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-5811534-A | PURINE-BASED COMPOUNDS FOR INCLUSION INTO OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5808027-A | ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5587469-A | USEFUL AS ?ANTISENSE AGENTS? THAT ARE CAPABLE OF SPECIFIC HYBRIDIZATION WITH A NUCLEOTIDE SEQUENCE OF AN RNA | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0742790-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0731807-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5543507-A | BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995014707-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030031655-A1 | Methods of light activated release of ligands from endosomes | LAMP2, PLAUR, CLTB | DRD3 2863/4885ALDH1A1 4432/4885MAOB 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.